ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Evogene (EVGN)
Evogene stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$0.36▼ -1.89%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Evogene in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Evogene
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Evogene a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $0.31 and $0.40; in 9 out of 10, between $0.25 and $0.50. Estimated annual volatility is 73%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $6.8M
- 52-week high
- $1.33
- 52-week low
- $0.35
- Revenue (12 months)
- $1.7M
- Revenue growth (YoY)
- -54.7%
- Gross margin
- -6.3%
- Operating margin
- -364.2%
- Net margin
- -203.1%
- Return on equity
- -182.7%
- Free cash flow (12 months)
- $-2.0M
- Beta
- 0.70
What this means
ATLAS does not publish a fair value for EVGN right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks EVGN has traded between $0.35 and $1.33. Today it is 72.7% below that high and 3% above its low.
On the business: revenue fell 54.7% year over year; net margin is 203.1%.
Its beta is 0.70: it tends to move less than the market.
About the company
Evogene Ltd. is a computational biology and chemistry company focused on life-science product discovery and development.
Want to see everything about Evogene?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Evogene do?
Evogene Ltd. is a computational biology and chemistry company focused on life-science product discovery and development.
What is the chance EVGN goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, EVGN ends the month between $0.31 and $0.40.
How big is Evogene and what is its P/E ratio?
Evogene's market capitalization is $6.8M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is EVGN?
ATLAS estimates annual volatility at 73%. In a typical month, half of the outcomes end between $0.31 and $0.40.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer